1. Medicare Part B spending on lab tests increased in 2021, driven by higher volume of COVID-19 tests, genetic tests, and chemistry tests Publication: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, December 2022 Subject(s): Clinical Chemistry TestsCOVID-19 TestingGenetic TestingGovernment RegulationMedicare Part B -- economicsUnited States
2. FDA’s work with the tri-agency task force for emergency diagnostics helped labs implement COVID-19 tests Publication: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, September 2022 Subject(s): Advisory CommitteesCOVID-19 TestingGovernment AgenciesGovernment RegulationLaboratoriesUnited StatesUnited States. Food and Drug Administration
3. FDA repeatedly adapted emergency use authorization policies to address the need for COVID-19 testing Publication: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, September 2022 Subject(s): COVID-19 TestingDevice ApprovalGovernment RegulationUnited StatesUnited States. Food and Drug Administration
